Compare Neurocrine Biosciences Inc (NBIX) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Ralph Lauren Corp — how do they compare? Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B), while Ralph Lauren Corp trades at $375.67 (market cap $22.41B). The key difference: Ralph Lauren Corp is the larger of the two by market cap, and Ralph Lauren Corp pays a 0.99% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | RL | |
|---|---|---|
Market Cap | $17.40B | $22.41B |
Sector | Health | Consumer Cyclical |
52-Week High | $180.55 | $414.25 |
52-Week Low | $123.10 | $283.34 |
Enterprise Value | $16.49B | $23.35B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% with strong bullish momentum. Recent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, underscore robust growth. The stock shows bullish technical signals with support at $170 and resistance at $173. Revenue growth accelerated to $2.86 billion in 2025, with net income margin improving to 21.55% in 2026 projections. Positive news highlights pipeline advancements and the Soleno acquisition.
Outlook remains positive with a consensus price target of $196.08, implying 13% upside. Key opportunities include sustained earnings growth and pipeline expansion, while risks involve clinical trial outcomes and competitive pressures. Institutional sentiment is strongly bullish with 86% buy ratings.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
